PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-2.49%
Negative revenue growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
-1.92%
Negative gross profit growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would suspect poor product pricing or inefficient production.
-2.60%
Negative EBIT growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-4.40%
Negative operating income growth while Medical - Pharmaceuticals median is 3.01%. Seth Klarman would check if structural or cyclical issues are at play.
-3.10%
Negative net income growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-3.10%
Negative EPS growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-3.10%
Negative diluted EPS growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Dividend cuts while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see if others maintain or grow payouts, highlighting a relative weakness.
-42.18%
Negative OCF growth while Medical - Pharmaceuticals median is 9.09%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-72.49%
Negative FCF growth while Medical - Pharmaceuticals median is 5.43%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
20.90%
10Y CAGR of 20.90% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that can compound over very long horizons.
20.90%
5Y CAGR of 20.90% while Medical - Pharmaceuticals is zero. Walter Schloss might see a slight improvement that could compound if momentum builds.
20.90%
3Y CAGR of 20.90% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest improvement overshadowing the broader sector’s stagnation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
89.60%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 19.48% over a decade. Joel Greenblatt might see a standout compounder of earnings.
89.60%
5Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 19.48%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
89.60%
3Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 1.04%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09